Benzinga's Top Initiations
October 03, 2013 at 07:29 AM EDT
Analysts at Canaccord Genuity initiated coverage on shares of Mast Therapeutics (NYSE: MSTX ) with a “buy” rating. The target price for Mast Therapeutics is set to $3. Mast Therapeutics' shares closed at $0.45 yesterday. Bank of America initiated coverage on shares of NPS Pharmaceuticals (NASDAQ: NPSP )